GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » Cyclically Adjusted Revenue per Share

Biogen (XSWX:BIIB) Cyclically Adjusted Revenue per Share : CHF0.00 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Biogen Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Mar. 2025 was CHF14.101. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 8.30% per year. And the median was 21.50% per year.

As of today (2025-06-26), Biogen's current stock price is CHF232.00. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was CHF0.00. Biogen's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 17.28. The lowest was 1.45. And the median was 5.56.


Biogen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.07 - - - -

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biogen's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


;
;

Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=14.101/134.9266*134.9266
=14.101

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 10.249 100.684 13.735
201509 11.614 100.392 15.609
201512 12.802 99.792 17.309
201603 12.199 100.470 16.383
201606 12.789 101.688 16.969
201609 13.111 101.861 17.367
201612 13.492 101.863 17.871
201703 13.038 102.862 17.102
201706 14.044 103.349 18.335
201709 13.987 104.136 18.123
201712 15.389 104.011 19.963
201803 14.021 105.290 17.968
201806 16.030 106.317 20.344
201809 16.493 106.507 20.894
201812 17.471 105.998 22.239
201903 17.724 107.251 22.298
201906 18.767 108.070 23.431
201909 19.361 108.329 24.115
201912 20.255 108.420 25.207
202003 19.587 108.902 24.268
202006 21.767 108.767 27.002
202009 19.649 109.815 24.142
202012 16.445 109.897 20.190
202103 16.436 111.754 19.844
202106 16.537 114.631 19.465
202109 16.834 115.734 19.626
202112 16.528 117.630 18.958
202203 15.446 121.301 17.181
202206 16.490 125.017 17.797
202209 16.027 125.227 17.268
202212 15.558 125.222 16.764
202303 14.964 127.348 15.855
202306 14.516 128.729 15.215
202309 14.942 129.860 15.525
202312 13.547 129.419 14.123
202403 13.361 131.776 13.680
202406 14.462 132.554 14.721
202409 13.713 133.029 13.909
202412 14.367 133.157 14.558
202503 14.101 134.927 14.101

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biogen  (XSWX:BIIB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 17.28. The lowest was 1.45. And the median was 5.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » Cyclically Adjusted Revenue per Share
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.